Go Deep
KYORIN Pharmaceutical Co., Ltd.
KYORIN Pharmaceutical Co., Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,796 | 29.4 | 0.45 | 0.17 | 671.95 |
KYORIN Pharmaceutical Co., Ltd. Quarterly Results
| Line Item | Jun 2026 | Jun 2025 |
|---|---|---|
| EPS | 14.3 | 36.6 |
KYORIN Pharmaceutical Co., Ltd. Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 126,257,000,000.0 | 130,087,000,000.0 | 119,532,000,000.0 | 113,270,000,000.0 |
| Net Profit | 3,448,000,000.0 | 9,086,000,000.0 | 5,475,000,000.0 | 4,723,000,000.0 |
| EPS | 60.0 | 158.2 | 92.7 | 82.4 |
KYORIN Pharmaceutical Co., Ltd. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 195,455,000,000.0 | 193,618,000,000.0 | 177,627,000,000.0 | 176,045,000,000.0 | — |
| Total Liabilities | 53,030,000,000.0 | 57,334,000,000.0 | 46,894,000,000.0 | 50,585,000,000.0 | — |
| Total Equity | 142,425,000,000.0 | 136,284,000,000.0 | 130,733,000,000.0 | 125,460,000,000.0 | — |
KYORIN Pharmaceutical Co., Ltd. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 7.7%Receivables 24.2%Inventory 34.7%Fixed assets (tangible) 15.6%Intangible assets 2.1%Long-term investments 9.7%Other assets 6.0%
How it's funded — Mar 2026
Short-term debt 1.5%Long-term debt 10.5%Payables 7.4%Other liabilities 7.8%Shareholders' equity 72.9%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 15,081.0 | 16,514.0 | 13,985.0 | 19,394.0 |
| Receivables | 47,341.0 | 47,583.0 | 47,714.0 | 47,291.0 |
| Inventory | 67,788.0 | 65,730.0 | 53,400.0 | 48,025.0 |
| Fixed assets (tangible) | 30,506.0 | 30,303.0 | 28,950.0 | 25,834.0 |
| Intangible assets | 4,085.0 | 4,757.0 | 5,088.0 | 5,393.0 |
| Long-term investments | 18,863.0 | 20,042.0 | 22,106.0 | 22,979.0 |
| Other assets | 11,791.0 | 8,689.0 | 6,384.0 | 7,129.0 |
| Liabilities & equity | ||||
| Short-term debt | 2,873.0 | 7,600.0 | 20,300.0 | 10,300.0 |
| Long-term debt | 20,444.0 | 20,235.0 | 435.0 | 10,636.0 |
| Payables | 14,441.0 | 15,517.0 | 14,265.0 | 13,762.0 |
| Other liabilities | 15,272.0 | 13,982.0 | 11,894.0 | 15,887.0 |
| Shareholders' equity | 142,425.0 | 136,284.0 | 130,733.0 | 125,460.0 |
| Net tangible assets | 138,340.0 | 131,527.0 | 125,645.0 | 120,067.0 |
KYORIN Pharmaceutical Co., Ltd. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 6,381,000,000.0 | 3,506,000,000.0 | 1,549,000,000.0 | 2,008,000,000.0 | — |
| Investing Activities | -1,644,000,000.0 | -6,323,000,000.0 | -3,187,000,000.0 | -6,275,000,000.0 | — |
| Financing Activities | -7,956,000,000.0 | 3,952,000,000.0 | -3,347,000,000.0 | -3,363,000,000.0 | — |